Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 12:13:62.
doi: 10.3389/fnins.2019.00062. eCollection 2019.

The Brain NGF Metabolic Pathway in Health and in Alzheimer's Pathology

Affiliations
Review

The Brain NGF Metabolic Pathway in Health and in Alzheimer's Pathology

A Claudio Cuello et al. Front Neurosci. .

Abstract

Emerging research has re-emphasized the role of the cortical cholinergic system in the symptomology and progression of Alzheimer's disease (AD). Basal forebrain (BF) cholinergic nuclei depend on target-derived NGF for survival during development and for the maintenance of a classical cholinergic phenotype during adulthood. In AD, BF cholinergic neurons lose their cholinergic phenotype and function, suggesting an impairment in NGF-mediated trophic support. We propose that alterations to the enzymatic pathway that controls the maturation of proNGF to mature NGF and the latter's ulterior degradation underlie this pathological process. Indeed, the NGF metabolic pathway has been demonstrated to be impaired in AD and other amyloid pathologies, and pharmacological manipulation of NGF metabolism has consequences in vivo for both levels of proNGF/NGF and the phenotype of BF cholinergic neurons. The NGF pathway may also have potential as a biomarker of cognitive decline in AD, as its changes can predict future cognitive decline in patients with Down syndrome as they develop preclinical Alzheimer's pathology. New evidence suggests that the cholinergic system, and by extension NGF, may have a greater role in the progression of AD than previously realized, as changes to the BF precede and predict changes to the entorhinal cortex, as anticholinergic drugs increase odds of developing AD, and as the use of donepezil can reduce rates of hippocampal and cortical thinning. These findings suggest that new, more sophisticated cholinergic therapies should be capable of preserving the basal forebrain thus having profound positive effects as treatments for AD.

Keywords: Alzheimer’s disease; basal forebrain cholinergic nuclei; cholinergic system; nerve growth factor; trophic support.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Schematic representation of the NGF metabolic pathway under physiological conditions and its deregulation in the Alzheimer’s pathology, explaining the “trophic disconnect” of NGF-dependent cholinergic neurons of the basal forebrain.

Similar articles

Cited by

References

    1. Adlimoghaddam A., Neuendorff M., Roy B., Albensi B. C. (2018). A review of clinical treatment considerations of donepezil in severe Alzheimer’s disease. CNS Neurosci. Therapeut. 24 876–888. 10.1111/cns.13035 - DOI - PMC - PubMed
    1. Allard S., Jacobs M. L., Do Carmo S., Cuello A. C. (2018). Compromise of cortical proNGF maturation causes selective retrograde atrophy in cholinergic nucleus basalis neurons. Neurobiol. Aging 67 10–20. 10.1016/j.neurobiolaging.2018.03.002 - DOI - PubMed
    1. Allard S., Leon W. C., Pakavathkumar P., Bruno M. A., Ribeiro-da-Silva A., Cuello A. C. (2012). Impact of the NGF maturation and degradation pathway on the cortical cholinergic system phenotype. J. Neurosci. 32 2002–2012. 10.1523/JNEUROSCI.1144-11.2012 - DOI - PMC - PubMed
    1. Appel S. H. (1981). A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease. Ann. Neurol. 10 499–505. 10.1002/ana.410100602 - DOI - PubMed
    1. Auburger G., Heumann R., Hellweg R., Korsching S., Thoenen H. (1987). Developmental changes of nerve growth factor and its mRNA in the rat hippocampus: comparison with choline acetyltransferase. Dev. Biol. 120 322–328. 10.1016/0012-1606(87)90235-1 - DOI - PubMed